How mRNA is misspliced in acute myelogenous leukemia (AML)?
Metrics: PDF 1478 views | HTML 1770 views | ?
Oncovirologie et Biothérapies, CNRS UMR5239, Faculté de Médecine Lyon Sud, Ecole Normale supérieure de Lyon, Hospices Civils de Lyon, Pierre Bénite, France
* These authors equally contributed
Eric Wattel, e-mail: email@example.com
Received: July 30, 2014 Accepted: July 31, 2014 Published: November 8, 2014
Approximately one-third of expressed genes are misspliced in AML, opening the possibility that additional factors than splicing factor mutations might cause RNA missplicing in these diseases. AML cells harbor a constellation of epigenetic modifications and regularly express large amounts of WT1 transcripts. Histone acetylation/methylation and DNA CpG methylation favor either exon skipping or inclusion, mainly through interfering with RNA Pol II-mediated elongation. This can result either from the binding of various factors on Pol II or alternatively from the recruitment of DNA binding factors that create roadblocks to Pol II-induced elongation. WT1 exhibits pleiotropic effects on mRNA splicing, which mainly result from the binding properties of WT1 via its zinc fingers domains to DNA, RNA, and proteins. Through the repression of the kinase SRPK1, WT1 modifies the splicing of VEGF, which plays important roles in hematopoiesis and angiogenesis. At the protein level, WT1 interacts with the splicing factors U2AF2, WTAP, and RPM4. Therefore, AML cells appear to have acquired numerous properties known to interfere with mRNA splicing. The challenge is now to elucidate these links in order to trigger mRNA splicing at the therapeutic level.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.